

# Biomix Network LTD/INC (India/USA)

## **RECEPTOL<sup>®</sup>**

Immunity Shield for unmet medical needs

## **Lab on a Chip**

Handheld Detection of Virus, Bacteria, Bio/Nuclear Hazard, and Pollutants

## **Hospital on a Chip**

AI based Knowledge Acquisition Tools (AIKAT)

**Dr. Pawan Saharan, MS, PhD & Post Doc (WVU/Stanford)**

[drpawan@biomix.in](mailto:drpawan@biomix.in), WA # 8291084108, [www.biomix.in](http://www.biomix.in)

# Sustainable - Dairy Waste to life-saving drug

**Glaxo & IPOS Global Market Research Yearly Estimates**

*USD 5.6 Billion - USA*

*USD 15 Billion - Worldwide*

Estimated Time to Market : 3-6 months

Help 8 Billion Globally!




## In Brief

- Founded in 1996 and registered in India and US (Delaware), company is a privately held Nano-biotech pharmaceutical company. Drug Discovery in 2001.
- The R&D focused outfit is led by Dr. Pawan Saharan, MS, Ph.D. (West Virginia) with over 25 years of experience in healthcare
- Advised by an eminent Board with over 200 years combined experience in Pharma /Medical, Nano- bio-technology & Dairy Tech. fields, and a worldwide research team
- 3 product lines developed, one launched - the New Generation Immune-Modulator & Broad Spectrum Anti Viral Drug (RECEPTOL®).
- Drug is effective against a broad spectrum of viral diseases/ immune disorders. Has undergone three phase of clinical trials and is ready for commercialization.
- Company manufacturing plant and R&D center located at the largest cooperative dairy in the world – AMUL, India. US Manufacturing is planned for January through June 2024
- Government Ministry of Science & Technology advanced INR 12 Crores as soft loan for setting up the manufacturing facility.

## Product Lines



Demonstrate expertise, & credibility in the field of nutrition, immunity, & health. The drug is being marketed and distributed under the name RECEPTOL®



AI Knowledge Acquisition Tool (AIKAT) reduced time for initial discovery of RECEPTOL®. Virtual Speciality Hospital, Last mile delivery. Real Time Telemedicine, Emergency Services, Drug Delivery and Discovery



Hand-held AI based laser microcantilever detection of pollutants, chemical, biological, and nuclear warfare. Developed for fast, inexpensive detection of TB antigens in human blood, diagnostics of arbitrary bio-chemical compounds in bodily fluids. Efficient Diagnosis and Prevention of Disease

## Vision

**HEALTH FOR ALL via affordable and effective healthcare**

## Mission

**Develop & manufacture cost effective, safe products for prevention & treatment of all communicable & immune disorders**

## Goal

**Helping 8 billion lives globally**

# Global Health Problems – Millions Suffer from



**Cancer**



**Infectious Disease**



**Medical Unmet Needs**

## INDIAN SOLUTION TO GLOBAL HEALTH PROBLEMS

What if there was a way to treat all immunity disorders via

**RECEPTOL®**, not only strengthens body's own immune system but also prevents recurrent infections in Cancer, Infectious Disease, environmental and war connected health issues, & help find solutions to unmet medical needs.

**2018 Nobel Prize for Cancer Immunotherapy supports RECEPTOL®**  
**Claims per US & EU granted Patents for All Immunity disorders**

Medicine Laureate Dr. Tasuku Honjo  
Professor at Kyoto University.

Medicine Laureate Dr. James P. Allison  
Chairman of immunology at the University  
of Texas M.D. Anderson Cancer Center

**Identified Checkpoint PD-1**

**Identified Checkpoint CTLA-4**

*T-cells can identify and kill infected, damaged or cancerous cells. Cancer cells can avoid destruction by taking advantage of a switch on the T-cell called an immune checkpoint. The checkpoint can shut down the T-cell and suppress the immune response, allowing the cancer to grow unchecked. The checkpoint discoveries by Dr. Allison and Dr. Honjo made it possible to develop drugs that would stop the checkpoints from working, so that the T-cells would be free to fight cancer, taking the brakes off the immune system.*

**RECEPTOL®**

**Cell surface checkpoint inhibitors can physically block the checkpoint,  
which frees the immune system to attack the cancer**



Innovations in Pharma, Healthcare & Diagnostics

PANDEMICS

ENVIRONMENT

WAR ISSUES

PROBLEM

Immunity Drug



**RECEPTOL<sup>®</sup>**  
Immune Booster &  
Cancer Checkpoint  
Blocker

Lab on Chip



Handheld AI-based  
laser microcantilever  
detection of pollutants  
&  
Chemical, Biological,  
and Nuclear Warfare


Hospital on Chip



Global Hub  
Last Mile Delivery  
Telemedicine  
Tediagnosis  
  
AI - Virtual Hospital  
  
Pharma, CRO, Drug  
Discovery

Globally Patented SOLUTIONS

# Founders



**Dr. George Wald**

- 2 Nobel Prizes
- Vit A Inventor
- Biomix Advisor



**Joseph Weizenbaum**

- Father of AI
- Inventor of 1<sup>st</sup> Robot
- Biomix Advisor



**Dr. Pawan Saharan**

- Biomix Founder
- Inventor:  
RECEPTOL®
- Patent holder for  
58/108 Disease  
Resolutions

## Journey of RECEPTOL®

After 18 years of research, we have successfully isolated Nano peptides from bovine colostrum and conducted global clinical studies on subjects suffering from Cancer, Infectious Disease viz Covid, AIDS, Swine Flu & Immunity diseases especially to address medical unmet needs based on stand alone AIDS therapy model.

**RECEPTOL®** Active ingredients consist of Patented Nano – Informational Peptides extracted from mammalian colostrum via Ultra Nano filtration Technology having sequence id 1-8 ( provided in the US Patent) & Proline Rich Poly Peptides (PRPs)  
<https://patents.google.com/patent/US9249188B2/en>

RECEPTOL® clinical trials & their meta-analysis on **25,301** subjects including healthy population can be accessed at data room at [www.biomix.in](http://www.biomix.in)

Publications in leading peer reviewed medical journals on global studies just concluded are in progress with New England Journal of Medicine & Nature.

US media published a feature on the invention journey


<http://medicaltraveltoday.com/spotlight-interview-pawan-saharan-founder-ceo-biomix-network-inc/>

Government of India Health Minister recognized the release of a Book on RECEPTOL® - “The Next Wonder Drug Creating a Paradigm shift from prevention to treatment providing health for All.”

**BIOMIX NETWORK LTD/INC**  
Engineered by Intellect. Driven by Ethics



### Market Research By Glaxo IPSOS USA



LOCATION

USA, UK, & India.



SAMPLE SIZE

800 Respondents



TARGET POPULATION

Households of SEC "A" in society  
consuming HFDs & FMCG  
products.



PRODUCT

RECEPTOL® powder  
additive

**Innovation : based on consumer research conducted by IPSOS(via Glaxo) & IRMA (via Amul) on 1000 consumers families giving top box responses with very high ITP scores.**

**The USP against all other Colostrum products available globally is clinically proven efficacy & safety well accepted by global, US Patent granting 58 indications including all immune & viral disorders**

## What is RECEPTOL®?

RECEPTOL® is an innovative, single solution to boost Immunity and solves a majority of health issues related to it.

1

## What it consists of ?

Active Ingredients consist of Patented Nano-Informational Peptides extracted from mammalian bovine colostrum via Ultra Nano filtration Technology with sequence id 1-8 & Proline Rich Poly Peptides (PRPs)

2



3

## What are PRPs ?

PRPs are a class of nano-informational peptides consisting of oligo-ribonucleotides attached to a peptide molecule that act as an immunity stimulator via immune-modulation and anti-viral/bacterial activity.


## How is it absorbed ?

Absorbed through the buccal mucosa or Gut  
Distributed all over the body through the blood streams.

**Crosses blood brain barrier to reach Pituitary gland which acts as central hub in building body's immune system naturally.**

4

## RECEPTOL® the Differentiator




**RECEPTOL® Acts when All Fail**

Patent No – US 9,249,188 B2

**Builds bodies own  
immune system.**

**Stimulates  
Tumor Necrosis  
Factors NK cells  
Interleukin-1 to IL-11,  
Interferon- $\alpha$ , INF- $\gamma$ .**



**Mode of Action of Receptol® drastically differs from other treatments/vaccines in pipeline since it blocks entry of ALL viruses, by lockdown & augments immunomodulation in unique patterns not only for COVID-19 but all Immunity diseases including CANCER**




***Source: RECEPTOL® Book released by Dr Harsh Vardhan,  
Chairman WHO Board of Directors, Health and Family Welfare Minister, Government of India***



PRPs get absorbed in the blood through buccal mucosa and crosses the Blood Brain Barrier



- Radha108 (PRP) promotes differentiation of B cells, differentiation & maturation of macrophages and monocytes.
- Activates natural killer (NK) cells, cytotoxic cells of the innate immune system.
- Mitigates cell fusion and docks on HIV glycoprotein like Gp120, 180,160 and 41 mimicking receptor on the cell surface closing entry of viruses.



- Stimulates production of cytokines IL-1 to IL-11, TNF- $\alpha$ , INF- $\gamma$ .
- Stimulates the maturation of immature thymocytes into either helper or suppressor T cells
- Radha108 also functions as a molecular signalling device which works through receptors on target cell surfaces



Electron Micrograph Showing both HIV & Coronavirus unable to infect cells via Radha108  
Nona-peptides Competitive inhibition on Cell surface with viral lock down

## RECEPTOL® Mode of Action in HIV/ AIDS




Figure 4. Pictures of HIV under a microscope.






Figure 5. Graphic of how RECEPTOL® protects human T-Cells.

## RECEPTOL® Mode of Action in Coronavirus Scenario



Spike Glycoprotein (S)

Radha 108 Toll like Receptor



Radha 108 Toll like  
**RECEPTOL®** nanopeptides  
can block the attachment of  
S protein of Coronavirus as  
depicted above







Collection of colostrum from dairy societies across Maharashtra



Transport and freezing at -18



Processing of colostrum whey




Pre-filtration Nano-and altro filtration



Formulation



Delivery to the market



### \*Global Launch

Based on

1. Global Market Research by IPSOS USA
2. Indian Market Research by Institute of Rural Management
3. Phase 4 by Lupin Laboratory in India, Himalayan Health Ltd Australia, Pharm Echo Russia,

### \*Global Launch Strategy

Maximize revenue by

- Out licensing as a Nutraceutical to large MNCs like Unilever.
- Launch as an Immunity Booster in North America & Europe to meet Pandemic (e.g. COVID) challenge.

Globally **RECEPTOL®**

received 65 Product Patents for 58 indications in North America, Canada, EU, UK, South Africa & India with the latest being granted in February 2024

Phase I of the Clinical Trial was conducted in the United States to ascertain the safety of the product along with pre-clinical acute & sub acute studies done at National Institute of Nutrition Hyderabad.

Phase II – IV studies were conducted in Africa & India for efficacy of RECEPTOL® using AIDS as a model for all viral/immune compromised conditions

Meta Analysis including study on Allergy, Asthma, Chronic fatigue syndrome & Endometriosis were conducted in the US by doctors who dispensed the products to the patients directly. Similar studies were conducted in Australia & India on Swine Flu whose results can be seen in the links given in the History of RECEPTOL® slide

- US Patent # 9,249,188 B2, granted in February 2016, for 58 indications.
- **Canadian** Patent # 2,789,787, granted June 2018, for the same 58 indications as the US patent.
- **European** Patent # EP 2 372 571 B1, granted in March 2019, for the same 58 indications.
- **Indian** Patent # 276911, granted in April 2019, for the same 58 indications as the US patent.

### **Safety and Efficacy achieved by global trials:**

Phase I : 12 cohort 30 days  
(completely safe) in Ohio,  
USA

Phase II : 30 cohort 90 days  
(highly effective with no side  
effects) in Nairobi – Kenya

Phase III : 60 cohort for 365  
days (highly effective with no  
side effects) in Rwanda,  
Africa

**Phase III** Indian Safety & Efficacy Mono Therapy Clinical Trials with Radha 108 Nano Peptide by Government of India, Ministry of Health/National AIDS Control and Monitored by Indian Council of Medical Research/NARI\* by US PATH accredited organization

**Study I** : 50 HIV Positive Patients at  
Tertiary Care LTMG Hospital Sion, Mumbai  
(Clinical trial registry #: CTRI-2012-08-002931)

**Study II** : 51 HIV Positive Patients at  
Tertiary Care LTMG Hospital, Sion, Mumbai  
(Clinical Trial registry #: CTRI-2012-09-002959)

# US Product Patent Granted For 58 indications Including SARS COVID

*“RECEPTOL’s unique Mode of Action led to US & EU Govt granting product patents for 58 indications: starting from the common cold, influenza, allergies, asthma, Rheumatoid Arthritis, Swine Flu, Endometriosis, Chronic Fatigue Syndrome, etc. to life threatening HIV, and Cancer with US Product Patent # 9,249,188 along with Canadian, European, Indian, South African & Singapore patents. RECEPTOL® has also been approved by Government of India for National Health Program.”*

Patent No :-USA,249,188B2

Date of Patent :-Feb,02,2016




(12) <b>United States Patent</b> Saharan		(10) Patent No.: <b>US 9,249,188 B2</b>
		(43) Date of Patent: <b>Feb. 2, 2016</b>
(54) <b>MAMMALIAN COLOSTRUM DERIVED NANOPETIDES FOR BROADSPECTRUM VIRAL AND RECURRENT INFECTIONS WITH A METHOD OF ISOLATION THEREOF</b>		2005/0103068 A1 * 6/2003 Arnoldson et al. 424/138.1 2005/0175297 A1 8/2005 Baslin et al. 2007/0123047 A1 * 9/2007 Roeb 424/185.1
(71) Applicant: Pawan Saharan, Maharashtra (IN)		FOREIGN PATENT DOCUMENTS
(72) Inventor: Pawan Saharan, Maharashtra (IN)		KR 20030024002 A 4/2002 WO 01/55199 A1 8/2001 WO 01/02781 A2 8/2001 WO 2005/081628 A2 9/2005
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 75 days.		OTHER PUBLICATIONS
(21) Appl. No.: 13/945,577		Blake, Bovine Colostrum, The Forgotten Miracle, Journal of the American Holistic Veterinary Medical Association Jul. 1999, vol. 18, No. 2, pp. 39-40.*
(22) Filed: Mar. 18, 2013		Posters Co-operative Group Ltd, Colostrum and Buttle Sales Got a Boost from SARS, 2003.*
(65) <b>Prior Publication Data</b> US 2013/0274177 A1 Oct. 17, 2013		Venuecity, Colostrum is a proven, effective immune system booster, Natural News, 2003.*
<b>Related U.S. Application Data</b>		Hong, S.Y. and Qin, Z.B., "Inhibitor of Binding 3" XP002566928, Aug. 2, 2005, retrieved from EBI Database accession No. Q4Q9P9.
(62) Division of application No. 13/142,327, filed as application No. PCT/IN2009/000749 on Dec. 29, 2009, now Pat. No. 8,518,454.		Stroff W.G. et al.: "Bovine colostrum as a biologic in clinical medicine: a review—Part II: clinical studies", Int. Journal of Clinical Pharmacology and Therapeutics, vol. 46, No. 5, pp. 211-225, May 1, 2008, XP009150270, ISSN: 0946-1965.
(30) <b>Foreign Application Priority Data</b> Dec. 27, 2008 (IN) 13/5/MUM/2008		Bisoli V., Van Renssen K., Cavadonchi F., Lazzi B., Pusileo L., "Colostrum stimulates the lymphoid tissue providing benefits in aged or immunodeficient people", Journal Biology Royal Harwood Agents, Oct.-Dec.; 5(4) 121-4; 1991; abstract only, full-text unavailable
(31) Int. Cl.		Gda, S. et al.: "Insulin-like growth factor-I, GH, insulin and glucagon concentrations in bovine colostrum and in plasma of dairy cows and neonatal calves around parturition", Comp. Biochem. Physiol., vol. 94A, No. 4, pp. 805-808, 1989.
A61K 38/00 (2006.01)		Shen, F.Y. et al.: "Effect of growth factors on cell proliferation and epithelialization in human skin", Journal of Surgical Research, vol. 59, pp. 236-244, 1995.
A61N 5/28 (2006.01)		Examination report of corresponding European patent application 09827810.1, issued on Mar. 20, 2013.
A61P 31/28 (2006.01)		* cited by examiner
A61K 38/20 (2006.01)		Primary Examiner — Kathleen R. Skowronski
C07K 3/00 (2006.01)		Assistant Examiner — Sergio Colla
A61K 35/20 (2006.01)		(74) Attorney, Agent, or Firm — Nash, Goldberg & Meyer, Tamara B. Hawkins
C07K 5/00 (2006.01)		
(52) U.S. Cl.		(57) <b>ABSTRACT</b>
CPC : C07K 7/08 (2013.01); A61K 35/20 (2013.01); A61K 38/00 (2013.01); A61K 36/20 (2013.01); C07K 5/00 (2013.01)		The present invention relates to nanopetides isolated from mammalian colostrums with vaccine like antiviral and immunomodulator activity via binding body's own immune system and attachment inhibition on the cell surface receptors.
(58) <b>Field of Classification Search</b> CPC : C07K 7/08; C07K 7/06 See application file for complete search history.		
(56) <b>References Cited</b> U.S. PATENT DOCUMENTS		
5,983,878 A 11/1997 Elisei et al.		
2002/0127279 A1 9/2002 Mathews		

- Product is completely safe w/ no side effects after 10 years follow up
- **Sample Size:** 25,000 (Including Control Group / Healthy population)
- **Scope:** HIV, Swine Flu, Allergy/Asthma, Rheumatoid Arthritis, Endometriosis & NCD, Chronic Fatigue Syndrome
- **Hypothesis:** Weight gain is an indication of wellness and overall health. No side effects with improved QoL showcases the safety and efficacy of the product.

### Conclusion:

Study reveals that RECEPTOL® oral spray therapy provides **significant efficacy & safety in all groups of patients suffering from communicable & Immunity diseases** with increased Quality of Life with increased weight gain in chronic patients.

Sr.No.	Stand Alone Receptol Therapy in Global clinical studies	No. of Patients
1	Healthy people	10,000
2	HIV Patient in USA, Africa, India	5000
3	Swine Flu	5000
4	Other Indications like allergy, asthma, Rheumatoid Arthritis, Chronic Fatigue Syndrome, Endometriosis Study etc.	5000



# RECEPTOL® Efficacy & Safety - Other Indications


Allergy, Asthma, Arthritis, Diarrhoea, Fever, Fatigue-malaise, Anaemia, Endometriosis

## CHANGES IN MEAN WEIGHT AMONG STUDY CASES

Duration (Weeks)	Mean weight ( $\pm$ SD) (N = 5000)
<b>Baseline</b>	<b>50.41 <math>\pm</math> 10.03</b>
<b>1</b>	<b>50.76 <math>\pm</math> 10.01</b>
<b>2</b>	<b>51.11 <math>\pm</math> 09.94</b>
<b>3</b>	<b>51.60 <math>\pm</math> 09.91</b>
<b>4</b>	<b>52.15 <math>\pm</math> 09.91</b>
Mean Diff. (Baseline – Wk1) (P value)	<b>*00.35 <math>\pm</math> 00.57 (0.001)</b>
Mean Diff. (Baseline – Wk2) (P value)	<b>*00.70 <math>\pm</math> 01.05 (0.001)</b>
Mean Diff. (Baseline – Wk3) (P value)	<b>*01.19 <math>\pm</math> 01.77 (0.001)</b>
Mean Diff. (Baseline – Wk4) (P value)	<b>*01.74 <math>\pm</math> 01.95 (0.001)</b>


By ANOVA

P<0.05, \* Significant



- After 1 week of treatment, mean weight showed a significant rise of 0.7% from baseline.
- After 2 week of treatment, mean weight showed a significant rise of 1.4% from baseline, similar trend was observed till the end of 4 weeks.





## Collaboration Options

### Pharma Drug Business

1. Manufacturing capacity for commercial supply to China and APAC
2. Manufacturing AND Commercial distribution in China and APAC
3. Manufacturing capacity for commercial supply to US and Europe
4. Manufacturing AND Commercial distribution in US to Europe

### Nutrient Business

1. Manufacturing capacity for nutrient supply
2. Nutrient supply network for global markets
  - a. New JV
  - b. Other CMOs
  - c. Commercial distribution partners





**Emergency MMS alerts**




**Tele Medicine  
online 2<sup>nd</sup> opinion**



**Clinical trials CRO s/w  
With MNC hosting**



**AI driven Virtual Specialty Hospital  
With online medical research**



**Lab & Hospital on Chip  
with Tele Diagnostic**



**GENESOFT  
New drug discovery s/w**

**Innovation Journey** - RECEPTOL® manufactured by Biomix was discovered by Dr. Pawan Saharan, MS, Ph.d. WVU, Stanford with eminent group of scientists including 2 times Nobel laureate Prof. George Wald from Harvard & Prof. Joseph Weizenbaum, MIT Founder Directors with 18 years of research and development with funding by the Department of Science & Technology, GoI.

**Product** - RECEPTOL®, made from Colostrum Nano-peptides helps people lead longer & healthier lives by building the body's immune system, thus aiding in prevention and cure for all communicable & Immunity diseases: Coronavirus, AIDS, Swine Flu, RA, Allergy etc.

**Active Ingredients (API)** - Patented Nano - Informational Peptides ( Class 4 Proline Rich Poly Peptides & Radha108).

**Mode of Action** - RECEPTOL® gets absorbed in the blood through the buccal mucosa and crosses the Blood-Brain-Barrier. It stimulates maturation of immature thymocytes into either helper or suppressor T cells. It stimulates secretion of Tumour Necrosis Factor & cytokines IL-1 to IL-11, INF-a, INF-y. Activates Natural Killer (NK) Cells, cytotoxic cells of the innate immune system by 5 times.

**Indications – Immunity Enhancer** for Recurrent infections in Cancer, Infectious Disease & medical unmet needs viz rare immunity disorders.

**USP-** Innovative with common Mode of Action for all viral infections, affordable, globally patented, broad spectrum anti-viral, immunomodulator, easy to administer, 100% natural with side effects, can be consumed by all and has no age or sex barriers.

**Global Patents** - US Product Patent # 9,249,188, Canadian, European, Indian, South African & Singapore for 58 diseases.

**Market Research:** Glaxo Consumer Healthcare conducted Global Consumer Research via IPSOS showing intention to purchase score of 97% of all medical and health professionals.

**Global Clinical Studies** - Global Safety & Efficacy monotherapy on AIDS & other indications: Highly efficacious and free of all side effects.

**Goal** - Helping 8 billion lives via safe, affordable and effective treatment & prevention of All communicable disease.



To meet the goal post of our common priority Vision in preventing current and future pandemics, we propose to use 21st Century Technology Innovation Receptol in improving health and wellbeing of more than an 8 billion people in India and abroad with Mumbai as a hub in tie up with GoM dairy and pharmaceutical industry.



Receptol Level2 global Manufacturing Plant requires 500 sq. meter built up area in cheese manufacturing plant in or around Greater Mumbai with investment from GOM, as was done with GOI for the pilot facility in Gujarat at Amul Dairy. This will generate an Estd. 5000 Cr. income and will benefit farmers in Maharashtra, create 2 lakh new jobs in the first 5 years, and > 25K Cr. income over 25 years. Biomix is looking for a 100 year lease of the facility and land at Aray colony against a 10% equity in the SPV with GOM.



We are looking for a 25 years business association in manufacturing and marketing of Receptol finish products by GoM dairy and local pharma industry to prevent all infections and enhance the health, nutrition, and general wellbeing of the common man; using the best of innovation and technology in a sustainable manner leading to drastic reduction in child & female mortality rate in India and abroad by over 50%.



Biomix will bring the proprietary technology developed in last 15 years with an investment of US dollar \$150M in collaboration with Pharma for a potential revenue of US\$ 1.45 billion in a span of 5 years with a profit before tax EBITDA US\$ 566 million, based on global market research conducted by Glaxo and IPSOS USA, prior to COVID pandemic.

Long COVID, new pandemics, environmental and war connected health challenges upscale the revenues estimates to \$1 Billion yearly, as per the Receptol roadmap.

**Founder CEO**

**Dr. Pawan Saharan, MS, Ph.D. ( JNU, WVU )**  
AMP (ASCI in tie up with Harvard business school )  
Best US graduate student scientist award by AAAS with  
fellowship at Stanford Medical Centre, Palo Alto, CA.  
Email id: [biomix108@gmail.com](mailto:biomix108@gmail.com) / [drpawan@biomix.in](mailto:drpawan@biomix.in)

**Clinical Director**

**Prof. Dr. Ali Irani - Ph.D. DPT ( Spain )**, Head of Department  
Physiotherapy & Sports Medicine, Nanavati Hospital, Mumbai  
Former Physiotherapist of Indian Cricket Team (12 years)

**Project Director**

**Amitabh Thakore, B. Tech., MBA (IIMA), MS (USA)**

**Business Advisor**

**Ranjit Shahani BE IIT, MBA Jamnalal Bajaj**  
Chairman Novartis South Asia

**Founder Directors include:**

**Late Prof George Wald, Harvard Medical Centre 2 times Nobel Prize Winner**  
**Prof Joseph Weizenbaum, Father of AI Founder Chair Robotics Comp science Dept. MIT**

**Medical Directors**

**Dr. S.H. Advani, MD, FICP, FNAMS**  
Oncologist & President - Asian Cancer Society  
Padamvibhusan awardee by President of India

**Dr. Sushil Indoria , MD**  
Medical Director Life care Hospital, Thane

**Dr. Sandhya Saharan, MD, DGO,**  
**Gynecologist and IVF specialist**

**Marketing Advisor**

**Sumeet Arora, COO YUM Group Companies in Canada**

**Business Development Manager**

**Hemangi Saharan, MBA**  
University of North Carolina, Chapel Hills, NC, USA

**Business Development Manager**

**Nicolas Corzo, Master in Strategic Management**  
Strategic Management and Partnerships (Global)

*EXD : We prepare status report*  
A. K. SHARMA IAS  
SECRETARY  
TO CHIEF MINISTER  
મુખ્ય મંત્રીશ્રીના સચિવ



*CM DGR 85211*  
Sachivalaya, Gandhinagar-382 010  
Phone 23232611 to 19 (0) Fax 23222101.  
Email : sec2cm@gujarat.gov.in  
સચિવાલય, ગાંધીનગર-૩૮૨ ૦૧૦.  
તા.રોમ :

To

Additional Chief Secretary,  
Agriculture and Co-operation Department,  
Sachivalaya, Gandhinagar

Dear Sir,

Kindly find enclosed herewith a letter dated February 28, 2007 received in this office about commissioning of Pilot Plant for RECEPTOL at Kheda Dairy unit which is in the line for obtaining FDA license for manufacturing the product. Hon. CM is very keen to know more about the feasibility of this project. In this regard, we would request you to kindly send us a detailed report about the proposal for commissioning of this plant to enable us to brief the Hon. CM at the earliest.

With kind regards,

Yours sincerely,

*(A. K. Sharma)*

Copy to :

✓ The Managing Director,  
Kaira District Co-operative Milk Producers' Union Limited,  
Anand - 388 001

Encl : As above





डॉ. हर्ष वर्धन  
Dr. Harsh Vardhan



FTS 77-610 / 2014/VIP/HFM  
स्वास्थ्य एवं परिवार कल्याण मंत्री  
भारत सरकार  
Minister of Health & Family Welfare  
Government of India

18 September, 2014

## MESSAGE

It gives me an immense pleasure to release the book, Health for All via Receptol®, authored by Dr. Pawan Saharan.

The book gives detailed account of health benefit of colostrum. I understand that its research & development programme, clinical trials & manufacturing facility at AMUL dairy was supported by Govt. of India.

I wish Dr. Pawan Saharan, Chairman of Biomix Network Ltd., the very best.

(Dr. Harsh Vardhan)



Dr. Neeraj Sharma  
Scientist 'G' & Head  
Technology Development and  
Transfer Division

भारत सरकार

विज्ञान और प्रौद्योगिकी मंत्रालय  
विज्ञान और प्रौद्योगिकी विभाग  
टेक्नोलॉजी भवन, नया महरौली मार्ग  
नई दिल्ली-110 016

GOVERNMENT OF INDIA  
MINISTRY OF SCIENCE AND TECHNOLOGY  
DEPARTMENT OF SCIENCE AND TECHNOLOGY  
TECHNOLOGY BHAVAN, NEW MEHRAULI ROAD  
NEW DELHI-110 016

D.O. No.

VII-PRDSF/93/05-06/TDT

Dated .....


26.10.2018

Dear Shri Ramsin Parmar,

We have received a request from Dr. Pawan Saharan, CEO, M/s Biomix Network Ltd. Navi Mumbai in which, he has requested to write to you a letter regarding support and funding from Department of Science & Technology, GoI with respect to project entitled, "Phase-III clinical trials and scaling up of a novel antiviral product, RECEPTOL for AIDS".

This to state the fact that Department of Science & Technology, under its scheme Drugs and Pharmaceuticals Research Programme, has funded the above mentioned project by the way of providing a loan of Rs. 12 crores to the M/s Biomix Network Ltd. New Mumbai for the Pilot Plant for Phase-III clinical trials and scaling up of a novel antiviral product, RECEPTOL for AIDS. The project was commissioned at your Amul Diary Khatraj Premises.

This is for your information and consideration please.

  
(Dr. Neeraj Sharma)  
Head(TDT)

Shri Ramsin Parmar  
Chairman, Amul Diary & GCMME  
Kaira District Co-operative Milk Producers' Union Ltd.  
AMUL DAIRY, AMUL DIARY ROAD  
ANAND-388 001 (GUJARAT)


Copy to :


Dr Pawan Saharan, CEO,  
M/s Biomix Network Ltd.  
Navi Mumbai- 400610

# BIOMIX NETWORK LTD/INC

Engineered by Intellect. Driven by Ethics

# MINISTRY OF HEALTH GoI CERTIFICATION

  
सचिव, स्वास्थ्य  
श्री. वि. के. सुबुराज, भा.प्र.से.  
सचिव  
Dr. V. K. SUBBURAJ, IAS  
Secretary

  
भारत सरकार  
स्वास्थ्य एवं परिवार कल्याण मंत्रालय  
राष्ट्रीय एड्स नियंत्रण संगठन  
राष्ट्रीय एड्स नियंत्रण कार्यक्रम  
6वां तल, चंद्रलोक भवन, 36 जान्पाथ, नई दिल्ली - 110001  
Government of India  
Ministry of Health & Family Welfare  
Department of AIDS Control  
National AIDS Control Organisation  
6th Floor, Chandralok Building, 36 Janpath, New Delhi - 110 001  
१०८/सेक.ए.ए.सी./२०१४ (डयू नं.)


07.05.2014

Dear Dr. Pawan Saharan,

We are pleased to inform you that Department of AIDS Control has decided to use RECEPTOL from June, 2014 for select patient population under Operational Study Programme.

With regards,

Yours

  
(Dr. V.K. SUBBURAJ)

Dr. Pawan Saharan  
Chairman & CEO,  
Biomix Network Ltd.,  
Thane (W)-400610  
MUMBAI (India)

6th Floor, Chandralok Building, 36 Janpath, New Delhi - 110001, Phones : 011-23325331, Fax : 011-23731746  
E-mail : secydac@gmail.com

अपनी एचआईवी अवस्था जानें, निकटतम सरकारी अस्पताल में मुफ्त सलाह व जाँच पाएँ  
Know Your HIV status, go to the nearest Government Hospital for free Voluntary Counselling and Testing

Department of Health & Family Welfare  
\*\*\*

Enclosed herewith is the Minutes of the meeting held on 10<sup>th</sup> January, 2005 in the Chamber of Health Minister on Health for all Programme via lab on chip, hospital on chip and wonder drug Receptol from Dr. Pawan Saharan, Chairman, Biomix Network Limited with Health Minister, Director General of Health Services, Drug Controller General of India and Director General, Indian Council of Medical Research. I shall ask the concerned officials to take immediate action on the Minutes after the kind approval of HFM.

(PRASANNA HOTA)  
Secretary (Health & Family Welfare)  
12<sup>th</sup> January, 2005

HFM

Secretary (Health & FW)  
Disty No. 129  
Date 12/1/05

of M/o HFM  
No. 129  
Date 12/1/05

Following was agreed:

1. Ministry of Health will conduct efficacy trials on the receptol for 50 HIV patients at two sites (Tambaram Hospital in Chennai and JJ Hospital in Mumbai) on Government cost to be coordinated by ICMR and NACO in consultation with Dr. Pawan Saharan, Chairman Biomix Network Ltd.

Dr. Pawan Saharan's company will provide the products free of cost (300 bottles for 50 patients for study of three months) and all local expenses incurred on the trail will be borne by Ministry of Health & Family Welfare.

Once the efficacy of the product is determined Ministry of Health will consider for its inclusion in National Health Programme by NACO and will prepare the feasibility report on manufacturing of receptol in India.

2. Ministry of Health will appraise the project proposal of Dr. Pawan Saharan for lab on chip and Hospital on chip to conduct rapid tests for HIV, Hepatitis, TB and Malaria and efficient health delivery respectively under the collaboration of Government Institutes and Hospitals.

3. Ministry of Health will find an appropriate Public Sector Company to explore possibilities of a joint venture partner with Biomix Network Ltd. for the said projects.

4. Director General Health Services, Drug Controller General of India, Director General, Indian Council of Medical Research and DG, NACO to coordinate and help Dr. Pawan Saharan through their respective Departments/organizations to implement the decisions taken in the said meeting with HFM.

*Dr. Ali Irani* (PhD PhD DPT)

Head of Department: **PHYSIOTHERAPY AND SPORTS MEDICINE**

Chairperson(International Affairs) Indian Association of Physiotherapists

Direct: 91-22-26172329

Email: [draliarani@gmail.com](mailto:draliarani@gmail.com)

[www.physiotherapyindia.org](http://www.physiotherapyindia.org)

To,  
The Health Minister of India  
Nirman Bhavan, New Delhi 110001

May 13, 2020

Subject: Real time solution to combat all viral infections including Covid-19 based on our personal experience

Dear Dr Harsh Vardhan,

We wish to share our experience from India's most respected & oldest Corporate hospital in Mumbai. Our strategy is to treat new Covid -19 patients in India and abroad with clinically proven Immunity immunity booster, Receptol.

I have personally visited Receptol plant in khatraj Gujarat located in AMUL dairy premises & strongly believe that it can help build the immunity of the masses to prevent communicable diseases including Covid-19 after total lockdown is lifted since its Mode of Action is similar to HIV infection.

We have used Receptol on HIV positive kids who did better inspite of being high risk as they lost their parents due to AIDS.

My personal experience of Receptol on 500+ children suffering from HIV and other viral infections in past 8 years who were tried on Receptol illustrates that all of them are healthy and immune to current infections.

Kindly request Indian Council of Medical Research & Ministry of health who approved it for HIV per NACO Secretary letter of 2014 to add to recommendation to use Receptol in current pandemic and make it available through primary healthcare centres in India.  
Please feel free to contact me should you or any other organisation need further information.

Thanking you for leading the Nation's healthcare with confidence to save 1.3 billion citizens.

With best Regards



Prof. Dr. Ali Irani